All patients
age >= 55 yr age >= 65 yr critical disease omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
Immunostimulants drugs in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Balcells, 2020 4.22 [0.33; 53.77]
4.22 [0.33 ; 53.77 ] Balcells, 2020 1 0% 58 NA not evaluable deathsdetailed results Balcells, 2020 3.26 [0.62; 17.12]
Darazam, 2021 1.21 [0.65; 2.25]
Li, 2021 1.04 [0.02; 53.73]
1.36 [0.76 ; 2.42 ] Balcells, 2020, Darazam, 2021, Li, 2021 3 0% 320 moderate not evaluable deaths (time to event analysis only)detailed results Balcells, 2020 3.26 [0.62; 17.12]
3.26 [0.62 ; 17.12 ] Balcells, 2020 1 0% 58 NA not evaluable clinical deteriorationdetailed results Balcells, 2020 1.46 [0.44; 4.81]
Li, 2021 0.52 [0.02; 15.78]
1.30 [0.42 ; 4.02 ] Balcells, 2020, Li, 2021 2 0% 152 low not evaluable clinical improvementdetailed results Balcells, 2020 0.91 [0.52; 1.60]
Darazam, 2021 1.37 [0.88; 2.13]
Li, 2021 1.76 [1.10; 2.81]
1.34 [0.94 ; 1.90 ] Balcells, 2020, Darazam, 2021, Li, 2021 3 36% 322 moderate not evaluable clinical improvement (14-day)detailed results Li, 2021 2.86 [1.24; 6.62]
2.86 [1.24 ; 6.62 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (28-day)detailed results Li, 2021 4.26 [1.10; 16.44]
4.26 [1.10 ; 16.44 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (7-day)detailed results Li, 2021 1.83 [0.41; 8.14]
1.83 [0.41 ; 8.14 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (time to event analysis only)detailed results Balcells, 2020 0.91 [0.52; 1.60]
Darazam, 2021 1.37 [0.88; 2.13]
Li, 2021 1.76 [1.10; 2.81]
1.34 [0.94 ; 1.90 ] Balcells, 2020, Darazam, 2021, Li, 2021 3 36% 322 moderate not evaluable death or ventilationdetailed results Balcells, 2020 0.67 [0.14; 3.26]
0.67 [0.14 ; 3.26 ] Balcells, 2020 1 0% 58 NA not evaluable mechanical ventilationdetailed results Balcells, 2020 2.98 [0.41; 21.61]
Li, 2021 0.52 [0.02; 15.78]
1.92 [0.35 ; 10.65 ] Balcells, 2020, Li, 2021 2 0% 94 low not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
Li, 2021 7.68 [0.91; 65.15]
3.59 [1.15 ; 11.21 ] Balcells, 2020, Li, 2021 2 0% 141 low not evaluable viral clearance (time to event analysis only)detailed results Li, 2021 1.74 [1.10; 2.75]
1.74 [1.10 ; 2.75 ] Li, 2021 1 0% 96 NA not evaluable viral clearance by day 14detailed results Li, 2021 1.74 [0.71; 4.29]
1.74 [0.71 ; 4.29 ] Li, 2021 1 0% 94 NA not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
Li, 2021 2.20 [0.95; 5.10]
2.32 [1.14 ; 4.73 ] Balcells, 2020, Li, 2021 2 0% 141 moderate not evaluable serious adverse eventsdetailed results Balcells, 2020 4.54 [0.20; 105.23]
4.54 [0.20 ; 105.23 ] Balcells, 2020 1 0% 58 NA not evaluable 0.5 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 15:46 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567
- roots T: 290
